Comparison of radiation regimens in the treatment of Glioblastoma multiforme: Results from a single institution

Radiation Oncology

Volumn 10, Issue 1, 2015, Pages

  Azoulay, Melissa ^a   Santos, Fabiano ^b   Souhami, Luis ^a   Panet Raymond, Valerie ^a   Petrecca, Kevin ^c   Owen, Scott ^a   Guiot, Marie Christine ^c   Patyka, Mariia ^d   Sabri, Siham ^a,d   Shenouda, George ^a   Abdulkarim, Bassam ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Glioblastoma; Hypofractionation; MGMT; Radiation; Temozolomide

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; ALKYLATING AGENT; DACARBAZINE; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURGERY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLIOBLASTOMA; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN METHYLATION; RADIATION DOSE FRACTIONATION; REPEAT PROCEDURE; SURVIVAL; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; BRACHYTHERAPY; BRAIN NEOPLASMS; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL TRIAL; COMPARATIVE STUDY; INTENSITY MODULATED RADIATION THERAPY; MORTALITY; PATHOLOGY; PROCEDURES; PROGNOSIS; RADIOTHERAPY PLANNING SYSTEM; SURVIVAL RATE;

AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRACHYTHERAPY; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; DACARBAZINE; DOSE FRACTIONATION; FEMALE; GLIOBLASTOMA; HUMANS; MALE; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED; SURVIVAL RATE;

EID: 84928783004     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/s13014-015-0396-6     Document Type: Article

References (31)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-96. doi:10.1056/NEJMoa043330.
2. Marko NF, Weil RJ, Schroeder JL, Lang FF, Suki D, Sawaya RE. Extent of resection of glioblastoma revisited: personalized survival modeling facilitates more accurate survival prediction and supports a maximum-safe-resection approach to surgery. J Clin Oncol. 2014;32(8):774-82. doi:10.1200/JCO.2013.51.8886.
3. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963-72. doi:10.1200/JCO.2009.26.3541.
4. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-66. doi:10.1016/S1470-2045(09)70025-7.
5. Laperriere N, Zuraw L, Cairncross G, Cancer Care Ontario Practice Guidelines Initiative Neuro-Oncology Disease Site Group. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. J European Soc Ther Radiol Oncol. 2002;64(3):259-73.
6. Hingorani M, Colley WP, Dixit S, Beavis AM. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or hope for the future? Br J Radiol. 2012;85(1017):e770-81. doi:10.1259/bjr/83827377.
7. Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin. 2006;24(16):2563-9. doi:10.1200/JCO.2005.04.5963.
8. Malmstrom A, Gronberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13(9):916-26. doi:10.1016/S1470-2045(12)70265-6.
9. Sultanem K, Patrocinio H, Lambert C, Corns R, Leblanc R, Parker W, et al. The use of hypofractionated intensity-modulated irradiation in the treatment of glioblastoma multiforme: preliminary results of a prospective trial. Int J Radiat Oncol Biol Phys. 2004;58(1):247-52.
10. Panet-Raymond V, Souhami L, Roberge D, Kavan P, Shakibnia L, Muanza T, et al. Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis. Int J Radiat Oncol Biol Phys. 2009;73(2):473-8. doi:10.1016/j.ijrobp.2008.04.030.
11. Ciammella P, Galeandro M, D'Abbiero N, Podgornii A, Pisanello A, Botti A, et al. Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: A 6 year single institutional experience. Clin Neurol Neurosurg. 2013;115(9):1609-14. doi:10.1016/j.clineuro.2013.02.001.
12. Reddy K, Damek D, Gaspar LE, Ney D, Waziri A, Lillehei K, et al. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2012;84(3):655-60. doi:10.1016/j.ijrobp.2012.01.035.
13. Floyd NS, Woo SY, Teh BS, Prado C, Mai WY, Trask T, et al. Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2004;58(3):721-6. doi:10.1016/S0360-3016(03)01623-7.
14. Jastaniyah N, Murtha A, Pervez N, Le D, Roa W, Patel S, et al. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme. Radiat Oncol. 2013;8:38. doi:10.1186/1748-717X-8-38.
15. Iuchi T, Hatano K, Kodama T, Sakaida T, Yokoi S, Kawasaki K, et al. Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys. 2014;88(4):793-800. doi:10.1016/j.ijrobp.2013.12.011.
16. Chen C, Damek D, Gaspar LE, Waziri A, Lillehei K, Kleinschmidt-DeMasters BK, et al. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2011;81(4):1066-74. doi:10.1016/j.ijrobp.2010.07.021.
17. Network NCc. NCCN Clinical Practise Guidelines in Oncology: Central nervous system. 2014. http://www.nccn.org .
18. Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol. 2008;9(1):29-38. doi:10.1016/S1470-2045(07)70384-4.
19. Lamborn KR, Chang SM, Prados MD. Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol. 2004;6(3):227-35. doi:10.1215/S1152851703000620.
20. Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. 2008;26(25):4189-99. doi:10.1200/JCO.2007.11.5964.
21. Stummer W, Meinel T, Ewelt C, Martus P, Jakobs O, Felsberg J, et al. Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery. J Neurooncol. 2012;108(1):89-97. doi:10.1007/s11060-012-0798-3.
22. Kreth FW, Thon N, Simon M, Westphal M, Schackert G, Nikkhah G, et al. Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy. Annals Oncol J European Soc Med Oncol. 2013;24(12):3117-23. doi:10.1093/annonc/mdt388.
23. De Bonis P, Anile C, Pompucci A, Fiorentino A, Balducci M, Chiesa S, et al. The influence of surgery on recurrence pattern of glioblastoma. Clin Neurol Neurosurg. 2013;115(1):37-43. doi:10.1016/j.clineuro.2012.04.005.
24. Shenouda G, Souhami L, Freeman CR, Hazel J, Lehnert S, Joseph L. Accelerated fractionation for high-grade cerebral astrocytomas. Preliminary treatment results. Cancer. 1991;67(9):2247-52.
25. Fiorentino A, Balducci M, De Bonis P, Chiesa S, De Filippo L, Mangiola A, et al. Can elderly patients with newly diagnosed glioblastoma be enrolled in radiochemotherapy trials? Am J Clin Oncol. 2015;38(1):23-7. doi:10.1097/COC.0b013e3182868ea2.
26. Roa W, Brasher PM, Bauman G, Anthes M, Bruera E, Chan A, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol. 2004;22(9):1583-8. doi:10.1200/JCO.2004.06.082.
27. Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012;13(7):707-15. doi:10.1016/S1470-2045(12)70164-X.
28. Minniti G, Lanzetta G, Scaringi C, Caporello P, Salvati M, Arcella A, et al. Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma. Int J Radiat Oncol Biol Phys. 2012;83(1):93-9. doi:10.1016/j.ijrobp.2011.06.1992.
29. Bauchet L, Zouaoui S, Darlix A, Menjot de Champfleur N, Ferreira E, Fabbro M, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro Oncol. 2014. doi:10.1093/neuonc/nou063.
30. Budach W, Gioioso D, Taghian A, Stuschke M, Suit HD. Repopulation capacity during fractionated irradiation of squamous cell carcinomas and glioblastomas in vitro. Int J Radiat Oncol Biol Phys. 1997;39(3):743-50.
31. Pedicini P, Fiorentino A, Simeon V, Tini P, Chiumento C, Pirtoli L, et al. Clinical radiobiology of glioblastoma multiforme: estimation of tumor control probability from various radiotherapy fractionation schemes. Strahlenther Onkol. 2014;190(10):925-32. doi:10.1007/s00066-014-0638-9.